Blog

• Sell in May and Go Away—Starting With These 3 Stocks

OR Royalties (NYSE:OR) reported a record first quarter of 2026, with President and CEO Jason Attew saying the company is “off to an impressive

• 3 Large Cap Laggards Poised to Rally

Optimum Communications (NYSE:OPTU) reported lower first-quarter revenue and a large net loss tied to a non-cash impairment charge, while executives said the

• SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?

OppFi (NYSE:OPFI) reported higher first-quarter 2026 revenue but lower adjusted earnings as elevated charge-offs offset growth in

Orion Office REIT (NYSE:ONL) said its first-quarter results reflected continued progress on leasing, asset sales and balance-sheet management, while its board and management continue to evaluate

• The Nasdaq's Historic Rally Doesn't Mean the Risk Is Gone

Montrose Environmental Group (NYSE:ONT), now operating under the Onterris brand, reported lower first-quarter revenue as severe winter

• On Holdings Sets Up for Marathon Rally: New Highs Are Coming

ON (NYSE:ONON) reported what executives described as an “outstanding” start to 2026, with first-quarter net sales surpassing CHF 800

JBS (NYSE:JBS) reported record first-quarter sales but lower profitability as executives said the global protein company faced difficult market conditions in U.S. beef, seasonal pressures

• 3 Stocks Ringing in The New Year With Large Buyback Announcements

Olin (NYSE:OLN) executives said the company expects a sharp sequential improvement in second-quarter earnings as higher pricing

Infinity Natural Resources (NYSE:INR) said its first quarter was marked by a significant expansion of its Appalachian footprint, following the late-February closing of its acquisition of Antero’s

• 3 small-cap biotechs with potential breakthroughs in 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric

• Doximity is the Facebook and LinkedIn of the Medical Community

Doximity (NYSE:DOCS) reported fiscal fourth-quarter revenue above the high end of its guidance and said it is entering what management

BitGo (NYSE:BTGO) reported sharply higher first-quarter revenue from a year earlier but a wider GAAP loss, as executives said softer digital asset market conditions and accounting treatment for new

Wrap Technologies (NASDAQ:WRAP) said first-quarter revenue rose 45% year-over-year as product sales for its BolaWrap 150 line accelerated, while management reiterated its goal of doubling revenue

• USA Rare Earth's $2.8B Power Play to Secure the Supply Chain

USA Rare Earth (NASDAQ:USAR) said its first quarter was marked by a series of strategic transactions intended to turn the company into a

• 3 Sector ETFs Catching Fire After Earnings Beats

Energous (NASDAQ:WATT) reported sharply higher first-quarter revenue and a narrower loss as management said the wireless power company is moving

• Top 4 Stocks With Notable Insider Buying

STAAR Surgical (NASDAQ:STAA) said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued

Seer (NASDAQ:SEER) reported lower first-quarter revenue but reaffirmed its full-year 2026 outlook, with management pointing to population-scale proteomics studies, an expanding publication base and

Sangoma Technologies (NASDAQ:SANG) lowered its full-year fiscal 2026 revenue outlook and said its board has launched a structured strategic review, as management described a business increasingly

QT Imaging (NASDAQ:QTI) reported sharply higher first-quarter 2026 revenue as scanner shipments more than doubled from the prior-year period, while management highlighted progress on reimbursement

Rapid Micro Biosystems (NASDAQ:RPID) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while

• Breakout Momentum Plays You Need to Know About

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025

• The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)

Microvision (NASDAQ:MVIS) said its first-quarter results showed early commercial traction from its expanded lidar portfolio

MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas

Marchex (NASDAQ:MCHX) said it is seeing improving momentum from new artificial intelligence-driven products and operating efficiencies as management outlined first-quarter 2026 results, updated